Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
William Bradley, MD, discusses 5-year follow-up results from the SOLO-1 trial, which aimed to assess the long-term efficacy and tolerability of maintenance olaparib for newly diagnosed advanced ovarian cancer.
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the tolerability and dose modifications of PARP inhibitor therapies for ovarian cancer in the United States.
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for commercially insured patients with advanced ovarian cancer, but not those covered under Medicare.